Kiniksa Pharmaceuticals International, plc $KNSA Position Lowered by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management LLC reduced its stake in Kiniksa Pharmaceuticals by 75.1%, ending the first quarter with only 41,412 shares, valued at approximately $920,000.
• Analyst ratings for Kiniksa Pharmaceuticals have shown varying opinions, with price targets ranging from $36.00 to $54.00, indicating a generally positive outlook despite recent fluctuations.
• Insiders at Kiniksa Pharmaceuticals have sold a total of 532,312 shares over the last quarter, reflecting significant changes in ownership among key executives.

ADAR1 Capital Management LLC decreased its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 75.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,412 shares of the company's stock after selling 124,994 shares during the period. ADAR1 Capital Management LLC owned 0.06% of Kiniksa Pharmaceuticals International worth $920,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of KNSA. GAMMA Investing LLC grew its position in shares of Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares during the last quarter. US Bancorp DE acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth $33,000. Asset Management One Co. Ltd. purchased a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth $41,000. Wealthquest Corp purchased a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth $42,000. Finally, Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at $61,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Up 0.6%

Shares of Kiniksa Pharmaceuticals International stock traded up $0.20 on Friday, hitting $35.71. The company's stock had a trading volume of 328,234 shares, compared to its average volume of 429,216. The firm has a fifty day moving average price of $30.95 and a 200-day moving average price of $26.54. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $35.84. The company has a market capitalization of $2.65 billion, a P/E ratio of 892.97 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on KNSA shares. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Wells Fargo & Company upped their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Finally, Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $41.17.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 29,325 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total value of $954,528.75. Following the completion of the transaction, the insider owned 57,403 shares in the company, valued at $1,868,467.65. This represents a 33.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $35.50, for a total transaction of $535,730.50. Following the sale, the chief operating officer owned 44,452 shares in the company, valued at $1,578,046. This represents a 25.34% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 558,403 shares of company stock valued at $18,078,671. 53.48% of the stock is owned by insiders.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.